Measurable Residual Disease in Acute Leukemia

Dr. Farhad Ravandi-Kashani

Professor,

Department of Leukemia,

Division of Cancer Medicine,

The University of Texas MD Anderson Cancer Center

Biography:

Dr. Farhad Ravandi is Janiece and Stephen A. Lasher, Professor of Medicine and Chief of Section of Acute Myeloid Leukemia in the Department of Leukemia at the University of Texas – M. D. Anderson Cancer Center.
He graduated from the University of London, England and undertook residency and fellowship training at the Baylor College of Medicine and The University of Texas M.D. Anderson Cancer Center. During this time he specialized in the management of hematological malignancies and stem cell transplantation. He then joined the University of Illinois at Chicago as the director of leukemia program and the interim director of stem cell transplant program for three years until he joined the Leukemia department of M. D. Anderson in 2003.
Dr. Ravandi is board certified in Internal Medicine, Hematology and Medical Oncology. His main areas of interests are therapy of acute myeloid leukemia, as well as rare leukemias including Philadelphia positive acute lymphoblastic leukemia, hairy cell leukemia and T-cell leukemias. He has authored several book chapters and many articles in peer-reviewed journals. He is a member of several professional societies including the American Society of Hematology, American Society of Clinical
Oncology, and Society of Hematological Oncology and is a member of editorial board of several journals.

Topic of Lecture:

Clinical Utility of Measurable Residual Disease Assessment in Acute Leukemia

Dr. Partow Kebriaei

Professor,

Department of Stem Cell Transplantation,

Division of Cancer Medicine,

The University of Texas MD Anderson Cancer Center

Biography:

Dr. Kebriaei received her B.S. degree from Yale University in 1993, and her M.D. degree from the University of Texas at Houston medical school in 1997. She went on to receive her Internal Medicine training at University of Texas Southwestern in Dallas, and completed a fellowship in Hematology and Oncology at the University of Chicago in 2000. She joined the stem cell transplant department at MD Anderson Cancer Center (MDACC) in 2003. Dr. Kebriaei’s research interests include therapy of leukemias, in particular acute lymphoblastic leukemia (ALL), and she has led the development of the transplant program in ALL. She is also interested in the development of novel transplant preparative regimens that may have less regimen-related toxicity, and increased disease efficacy. More specifically, she is interested in investigating the use of traditional chemotherapeutic agents in combination with cellular therapies and adoptive immunotherapy to develop more effective treatment regimens. Work toward this aim includes investigating the use CD19-directed T cell therapy for lymphoid malignancies, and investigating the use of mesenchymal stromal cells for the therapy of graft versus host disease. Finally, she has been involved in the development of the CARTOX committee, a cross-disciplinary committee to oversee the safe administration of cellular therapy treatments. Dr. Kebriaei is the principal investigator of 10 currently active phase I/II clinical trials at MDACC, has authored numerous reviews, book chapters, and papers, and serves as a reviewer for major hematology and oncology publications. She is an active member of hematology and oncology professional societies including American Association for Cancer Research, American Society of Hematology, American Society of Clinical Oncology, and American Society for Blood and Marrow Transplantation.